Valuation: Immunic, Inc.

Market Cap 102M 90.95M 84.2M 76.2M 144M 9.63B 145M 1.01B 396M 5.06B 383M 375M 16.13B P/E 2026 *
-2.08x
P/E 2027 * -3.07x
Enterprise Value -178M -158M -147M -133M -250M -16.78B -253M -1.76B -690M -8.82B -667M -653M -28.11B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immunic, Inc.

1 day+0.94%
1 week+12.31%
Current month-19.57%
1 month-30.93%
3 months-50.63%
6 months-16.97%
Current year+40.15%
1 week 6.8
Extreme 6.8
7.92
1 month 6.35
Extreme 6.35
11.12
Current year 5.37
Extreme 5.372
17.43
1 year 5.06
Extreme 5.062
17.43
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 2026-05-31
President 49 2024-07-11
Director of Finance/CFO 58 2020-04-16
Director TitleAgeSince
Director/Board Member 64 2019-11-18
Chairman 67 2026-05-15
Director/Board Member 59 2019-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26
BVF Partners LP
OtherCompany 25,370 0.1859%
9/16/26 Free

Director

25,370 0.1859%
8/6/26 Free

Director

50,740 0.3725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%+12.31%-9.04%-36.07% 101M
-0.21%-4.43%+44.40%+74.13% 66.34B
+0.82%+5.41%+8.05%+73.53% 54.82B
-0.22%+6.53%+11.68%+87.32% 52.92B
+3.28%+5.58%+26.51%+50.05% 44.09B
+0.51%+9.95%+22.40%+133.92% 43.72B
-1.15%+0.39%+263.21%+594.60% 42.13B
+0.10%+9.90%+16.11%+59.33% 33.96B
-7.13%-5.76%+27.97%-0.67% 26.17B
+0.69%+5.60%+36.60%+26.94% 23.37B
Average -0.25%+5.50%+44.79%+106.31% 38.76B
Weighted average by Cap. -0.08%+4.55%+49.99%+127.20%

Financials

2026 *2027 *
Net sales - -
Net income -138M -123M -114M -103M -194M -13.04B -197M -1.37B -536M -6.86B -518M -508M -21.85B -152M -135M -125M -113M -213M -14.32B -216M -1.5B -589M -7.52B -569M -557M -23.98B
Net Debt -280M -249M -231M -209M -394M -26.41B -398M -2.77B -1.09B -13.88B -1.05B -1.03B -44.24B -404M -360M -333M -301M -568M -38.11B -575M -3.99B -1.57B -20.03B -1.51B -1.48B -63.83B
Projected Income Statement - Annual - Immunic, Inc.
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
26-10-21 US$7.480 +0.94% 329,837
26-10-20 US$7.410 +6.01% 429,665
26-10-19 US$6.990 +0.29% 319,803
26-10-16 US$6.970 -1.83% 366,845
26-10-15 US$7.100 +6.61% 285,134
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immunic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
7.480USD
Average target price
43.09USD
Spread / Average Target
+476.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immunic, Inc.
  1. Stock Market
  2. Stocks
  3. IMUX Stock